These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31382411)

  • 21. MiR-371-5p facilitates pancreatic cancer cell proliferation and decreases patient survival.
    He D; Miao H; Xu Y; Xiong L; Wang Y; Xiang H; Zhang H; Zhang Z
    PLoS One; 2014; 9(11):e112930. PubMed ID: 25411783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p/LASP1 signaling axis.
    Wang A; Dai H; Gong Y; Zhang C; Shu J; Luo Y; Jiang Y; Liu W; Bie P
    J Exp Clin Cancer Res; 2019 Aug; 38(1):347. PubMed ID: 31395079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. miR-367 promotes epithelial-to-mesenchymal transition and invasion of pancreatic ductal adenocarcinoma cells by targeting the Smad7-TGF-β signalling pathway.
    Zhu Z; Xu Y; Zhao J; Liu Q; Feng W; Fan J; Wang P
    Br J Cancer; 2015 Apr; 112(8):1367-75. PubMed ID: 25867271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiRNA-615-5p functions as a tumor suppressor in pancreatic ductal adenocarcinoma by targeting AKT2.
    Sun Y; Zhang T; Wang C; Jin X; Jia C; Yu S; Chen J
    PLoS One; 2015; 10(4):e0119783. PubMed ID: 25856297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. WIPF1 antagonizes the tumor suppressive effect of miR-141/200c and is associated with poor survival in patients with PDAC.
    Pan Y; Lu F; Xiong P; Pan M; Zhang Z; Lin X; Pan M; Huang H
    J Exp Clin Cancer Res; 2018 Jul; 37(1):167. PubMed ID: 30041660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma.
    Wang C; Sun Y; Wu H; Yu S; Zhang L; Meng Y; Liu M; Yang H; Liu P; Mao X; Lu Z; Chen J
    Tumour Biol; 2015 Dec; 36(12):9447-56. PubMed ID: 26124009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CRM1/XPO1 expression in pancreatic adenocarcinoma correlates with survivin expression and the proliferative activity.
    Saulino DM; Younes PS; Bailey JM; Younes M
    Oncotarget; 2018 Apr; 9(30):21289-21295. PubMed ID: 29765539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-124 Suppresses Pancreatic Ductal Adenocarcinoma Growth by Regulating Monocarboxylate Transporter 1-Mediated Cancer Lactate Metabolism.
    Wu DH; Liang H; Lu SN; Wang H; Su ZL; Zhang L; Ma JQ; Guo M; Tai S; Yu S
    Cell Physiol Biochem; 2018; 50(3):924-935. PubMed ID: 30355947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer.
    Vorvis C; Hatziapostolou M; Mahurkar-Joshi S; Koutsioumpa M; Williams J; Donahue TR; Poultsides GA; Eibl G; Iliopoulos D
    Am J Physiol Gastrointest Liver Physiol; 2016 Jun; 310(11):G1124-37. PubMed ID: 27151939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells.
    Fukushima H; Yasumoto M; Ogasawara S; Akiba J; Kitasato Y; Nakayama M; Naito Y; Ishida Y; Okabe Y; Yasunaga M; Horiuchi H; Sakamoto E; Itadani H; Mizuarai S; Oie S; Yano H
    Mol Cancer; 2016 May; 15(1):32. PubMed ID: 27145964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-221 induces autophagy through suppressing HDAC6 expression and promoting apoptosis in pancreatic cancer.
    Yang Y; Sun Y; Wang H; Li H; Zhang M; Zhou L; Meng X; Wu Y; Liu P; Liu X; Zhang J; Tan X
    Oncol Lett; 2018 Dec; 16(6):7295-7301. PubMed ID: 30546469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.
    Neggers JE; Vanstreels E; Baloglu E; Shacham S; Landesman Y; Daelemans D
    Oncotarget; 2016 Oct; 7(42):68842-68850. PubMed ID: 27634897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered Nuclear Export Signal Recognition as a Driver of Oncogenesis.
    Taylor J; Sendino M; Gorelick AN; Pastore A; Chang MT; Penson AV; Gavrila EI; Stewart C; Melnik EM; Herrejon Chavez F; Bitner L; Yoshimi A; Lee SC; Inoue D; Liu B; Zhang XJ; Mato AR; Dogan A; Kharas MG; Chen Y; Wang D; Soni RK; Hendrickson RC; Prieto G; Rodriguez JA; Taylor BS; Abdel-Wahab O
    Cancer Discov; 2019 Oct; 9(10):1452-1467. PubMed ID: 31285298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic and biological significance of microRNA-192 in pancreatic ductal adenocarcinoma.
    Zhao C; Zhang J; Zhang S; Yu D; Chen Y; Liu Q; Shi M; Ni C; Zhu M
    Oncol Rep; 2013 Jul; 30(1):276-84. PubMed ID: 23612862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding XPO1 target networks using systems biology and mathematical modeling.
    Muqbil I; Kauffman M; Shacham S; Mohammad RM; Azmi AS
    Curr Pharm Des; 2014; 20(1):56-65. PubMed ID: 23530499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The lncRNA MALAT1 acts as a competing endogenous RNA to regulate KRAS expression by sponging miR-217 in pancreatic ductal adenocarcinoma.
    Liu P; Yang H; Zhang J; Peng X; Lu Z; Tong W; Chen J
    Sci Rep; 2017 Jul; 7(1):5186. PubMed ID: 28701723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1.
    Wang P; Chen L; Zhang J; Chen H; Fan J; Wang K; Luo J; Chen Z; Meng Z; Liu L
    Oncogene; 2014 Jan; 33(4):514-24. PubMed ID: 23334332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.
    Miyake T; Pradeep S; Wu SY; Rupaimoole R; Zand B; Wen Y; Gharpure KM; Nagaraja AS; Hu W; Cho MS; Dalton HJ; Previs RA; Taylor ML; Hisamatsu T; Kang Y; Liu T; Shacham S; McCauley D; Hawke DH; Wiktorowicz JE; Coleman RL; Sood AK
    Clin Cancer Res; 2015 Jul; 21(14):3286-97. PubMed ID: 25878333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-143 Targeting TAK1 Attenuates Pancreatic Ductal Adenocarcinoma Progression via MAPK and NF-κB Pathway In Vitro.
    Huang FT; Peng JF; Cheng WJ; Zhuang YY; Wang LY; Li CQ; Tang J; Chen WY; Li YH; Zhang SN
    Dig Dis Sci; 2017 Apr; 62(4):944-957. PubMed ID: 28194669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development.
    Zhang S; Hao J; Xie F; Hu X; Liu C; Tong J; Zhou J; Wu J; Shao C
    Carcinogenesis; 2011 Aug; 32(8):1183-9. PubMed ID: 21665894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.